{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:52:23Z","timestamp":1773273143361,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To compare outcomes for patients with recurrent or persistent papillary thyroid cancer (PTC) who had metastatic tumors that were fluorodeoxyglucose-positron emission tomography (FDG-PET) positive or negative, and to determine whether the FDG-PET scan findings changed the outcome of medical and surgical management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From a prospective thyroid cancer database, we retrospectively identified patients with recurrent or persistent PTC and reviewed data on demographics, initial stage, location and extent of persistent or recurrent disease, clinical management, disease-free survival and outcome. We further identified subsets of patients who had an FDG-PET scan or an FDG-PET\/CT scan and whole-body radioactive iodine scans and categorized them by whether they had one or more FDG-PET-avid (PET-positive) lesions or PET-negative lesions. The medical and surgical treatments and outcome of these patients were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between 1984 and 2008, 41 of 141 patients who had recurrent or persistent PTC underwent FDG-PET (n = 11) or FDG-PET\/CT scans (n = 30); 22 patients (54%) had one or more PET-positive lesion(s), 17 (41%) had PET-negative lesions, and two had indeterminate lesions. Most PET-positive lesions were located in the neck (55%). Patients who had a PET-positive lesion had a significantly higher TNM stage (<jats:italic>P<\/jats:italic> = 0.01), higher age (<jats:italic>P<\/jats:italic> = 0.03), and higher thyroglobulin (<jats:italic>P<\/jats:italic> = 0.024). Only patients who had PET-positive lesions died (5\/22 vs. 0\/17 for PET-negative lesions; <jats:italic>P<\/jats:italic> = 0.04). In two of the seven patients who underwent surgical resection of their PET-positive lesions, loco-regional control was obtained without evidence of residual disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients with recurrent or persistent PTC and FDG-PET-positive lesions have a worse prognosis. In some patients loco-regional control can be obtained without evidence of residual disease by reoperation if the lesion is localized in the neck or mediastinum.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-10-192","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T18:20:29Z","timestamp":1347906029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management"],"prefix":"10.1186","volume":"10","author":[{"given":"Jennifer MJ","family":"Schreinemakers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno R","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Munoz-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlon A","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insoo","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inne HM Borel","family":"Rinkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Gosnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen T","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlo H","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan-Yang","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,17]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","volume":"83","author":"SA Hundahl","year":"1998","unstructured":"Hundahl SA, Fleming ID, Fremgen AM, Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985\u20131995. Cancer. 1998, 83: 2638-2648. 10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1.","journal-title":"Cancer"},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/thy.2006.16.109","volume":"16","author":"DS Cooper","year":"2006","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM, American Thyroid Association Guidelines Taskforce: Management guidelines of patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006, 16: 109-142. 10.1089\/thy.2006.16.109.","journal-title":"Thyroid"},{"key":"1169_CR3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.beem.2008.10.001","volume":"22","author":"RJ Robbins","year":"2008","unstructured":"Robbins RJ, Larson SM: The value of positron emission tomography (PET) in the management of patients with thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2008, 22: 1047-1059. 10.1016\/j.beem.2008.10.001.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1210\/jc.2003-032004","volume":"89","author":"A Rouxel","year":"2004","unstructured":"Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, Hoang C, Aurengo A, Leenhardt L: Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2004, 89: 5362-5368. 10.1210\/jc.2003-032004.","journal-title":"J Clin Endocrinol Metab"},{"key":"1169_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/eje.0.1490293","volume":"149","author":"F Giammarile","year":"2003","unstructured":"Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F: Is [18\u2009F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?. Eur J Endocrinol. 2003, 149: 293-300. 10.1530\/eje.0.1490293.","journal-title":"Eur J Endocrinol"},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1245\/s10434-007-9611-5","volume":"15","author":"SE Finkelstein","year":"2008","unstructured":"Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL: Combined [18\u2009F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET\/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol. 2008, 15: 286-292. 10.1245\/s10434-007-9611-5.","journal-title":"Ann Surg Oncol"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/00000658-200112000-00012","volume":"234","author":"A Frilling","year":"2001","unstructured":"Frilling A, Tecklenborg K, G\u00f6rges R, Weber F, Clausen M, Broelsch EC: Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001, 234: 804-811. 10.1097\/00000658-200112000-00012.","journal-title":"Ann Surg"},{"key":"1169_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00259-006-0276-2","volume":"34","author":"M Zoller","year":"2007","unstructured":"Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, Lind P: Combined PET\/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imaging. 2007, 34: 487-495. 10.1007\/s00259-006-0276-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1169_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/01.mlg.0000154725.00787.00","volume":"115","author":"Z Nahas","year":"2005","unstructured":"Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP: The role of positron emission tomography\/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope. 2005, 115: 237-243. 10.1097\/01.mlg.0000154725.00787.00.","journal-title":"Laryngoscope"},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/cncr.23515","volume":"113","author":"M Rivera","year":"2008","unstructured":"Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM: Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008, 113: 48-56. 10.1002\/cncr.23515.","journal-title":"Cancer"},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1210\/jc.85.3.1107","volume":"85","author":"W Wang","year":"2000","unstructured":"Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ: Prognostic value of [18\u2009F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000, 85: 1107-1113. 10.1210\/jc.85.3.1107.","journal-title":"J Clin Endocrinol Metab"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejrad.2007.12.004","volume":"70","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Lee TH, Kim IJ, Kim YK: Clinical implication of F-18 FDG PET\/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol. 2009, 70: 17-24. 10.1016\/j.ejrad.2007.12.004.","journal-title":"Eur J Radiol"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00268-007-9361-3","volume":"32","author":"CS Grant","year":"2008","unstructured":"Grant CS, Thompson GB, Farley DR, Richards ML, Mullan BP, Hay ID: The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma. World J Surg. 2008, 32: 708-715. 10.1007\/s00268-007-9361-3.","journal-title":"World J Surg"},{"key":"1169_CR14","first-page":"1464","volume":"42","author":"BO Helal","year":"2001","unstructured":"Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A: Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med. 2001, 42: 1464-1469.","journal-title":"J Nucl Med"},{"key":"1169_CR15","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1089\/10507250152741028","volume":"11","author":"W Wang","year":"2001","unstructured":"Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ: Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001, 11: 1169-1175. 10.1089\/10507250152741028.","journal-title":"Thyroid"},{"key":"1169_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.surg.2007.09.015","volume":"142","author":"E Mirallie","year":"2007","unstructured":"Mirallie E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodere F: Therapeutic impact of 18FDG-PET\/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery. 2007, 142: 952-958. 10.1016\/j.surg.2007.09.015.","journal-title":"Surgery"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-10-192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:11:41Z","timestamp":1630530701000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-10-192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,17]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-10-192","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,17]]},"assertion":[{"value":"18 March 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"192"}}